BR112016023391A8 - processo para a preparação de um composto de fórmula viii, processo para a preparação de 4-(2-(metilssulfonil)pirimidin-4-il)piridin-2(1h)-ona (vii), compostos,composições farmacêuticas,benzenossulfonatos, ácidos p-toluenossulfônico,forma b de ácido p-toluenssulfônico, forma ii do ácido naftalendissulfônico - Google Patents

processo para a preparação de um composto de fórmula viii, processo para a preparação de 4-(2-(metilssulfonil)pirimidin-4-il)piridin-2(1h)-ona (vii), compostos,composições farmacêuticas,benzenossulfonatos, ácidos p-toluenossulfônico,forma b de ácido p-toluenssulfônico, forma ii do ácido naftalendissulfônico Download PDF

Info

Publication number
BR112016023391A8
BR112016023391A8 BR112016023391A BR112016023391A BR112016023391A8 BR 112016023391 A8 BR112016023391 A8 BR 112016023391A8 BR 112016023391 A BR112016023391 A BR 112016023391A BR 112016023391 A BR112016023391 A BR 112016023391A BR 112016023391 A8 BR112016023391 A8 BR 112016023391A8
Authority
BR
Brazil
Prior art keywords
acid
preparation
benzenesulfonates
acids
compounds
Prior art date
Application number
BR112016023391A
Other languages
English (en)
Other versions
BR112016023391A2 (pt
BR112016023391B1 (pt
Inventor
Chestakova Alexandra
Sha Chunbo
Zhang Haiming
Iding Hans
Stults Jeffrey
Zhang Jianqian
Li Jing
LIN Jinguang
MEIER Patrik
Zhang Tao
Gu Wei
LINGHU Xin
Wang Youchu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR112016023391A2 publication Critical patent/BR112016023391A2/pt
Publication of BR112016023391A8 publication Critical patent/BR112016023391A8/pt
Publication of BR112016023391B1 publication Critical patent/BR112016023391B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165Heterorings having nitrogen atoms as the only ring heteroatoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

processos, compostos, composições farmacêuticas, benzenossulfonatos, ácidos, formas a e b de ácido p-toluenssulfônico, formas i e ii do ácido naftalendissulfônico. a presente invenção se refere a um processo para a fabricação de um composto de fórmula (viiia) e formas de sais de (viiia) em que rc é um ácido sulfônico de arila.
BR112016023391-3A 2014-04-09 2015-04-08 Processo para a preparação de um composto de fórmula viii BR112016023391B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/075011 2014-04-09
CN2014075011 2014-04-09
PCT/CN2015/076083 WO2015154674A1 (en) 2014-04-09 2015-04-08 Process for the manufacturing of medicaments

Publications (3)

Publication Number Publication Date
BR112016023391A2 BR112016023391A2 (pt) 2017-08-15
BR112016023391A8 true BR112016023391A8 (pt) 2021-07-20
BR112016023391B1 BR112016023391B1 (pt) 2022-08-09

Family

ID=54287327

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122020014933A BR122020014933B8 (pt) 2014-04-09 2015-04-08 Compostos, composições farmacêuticas, benzenossulfonatos, forma a de ácido p-toluenossulfônico, forma b de ácido p-toluenssulfônico, forma i do ácido naftalenodissulfônico e forma ii do ácido naftalendissulfônico
BR112016023391-3A BR112016023391B1 (pt) 2014-04-09 2015-04-08 Processo para a preparação de um composto de fórmula viii

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122020014933A BR122020014933B8 (pt) 2014-04-09 2015-04-08 Compostos, composições farmacêuticas, benzenossulfonatos, forma a de ácido p-toluenossulfônico, forma b de ácido p-toluenssulfônico, forma i do ácido naftalenodissulfônico e forma ii do ácido naftalendissulfônico

Country Status (22)

Country Link
US (4) US20170022183A1 (pt)
EP (2) EP3129025B1 (pt)
JP (3) JP6723926B2 (pt)
KR (3) KR20230006043A (pt)
CN (3) CN112645927A (pt)
AR (1) AR099989A1 (pt)
AU (2) AU2015245743B2 (pt)
BR (2) BR122020014933B8 (pt)
CA (2) CA2945098C (pt)
ES (1) ES2733495T3 (pt)
HR (1) HRP20191306T1 (pt)
IL (2) IL248205B (pt)
MX (2) MX2016013162A (pt)
MY (2) MY196320A (pt)
NZ (1) NZ725450A (pt)
PL (1) PL3129025T3 (pt)
RU (1) RU2684102C2 (pt)
SG (1) SG11201608421XA (pt)
SI (1) SI3129025T1 (pt)
TW (2) TWI762806B (pt)
WO (1) WO2015154674A1 (pt)
ZA (1) ZA201607066B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2857649T3 (es) * 2012-03-01 2021-09-29 Array Biopharma Inc Inhibidores de serina/treonina cinasa
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
CN106029672B (zh) 2013-12-06 2019-03-29 基因泰克公司 丝氨酸/苏氨酸激酶抑制剂
ES2733495T3 (es) 2014-04-09 2019-11-29 Genentech Inc Proceso para la fabricación de medicamentos
TN2018000119A1 (en) 2015-11-09 2019-10-04 Astrazeneca Ab Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
AU2017249229A1 (en) 2016-04-15 2018-10-04 Genentech, Inc. Diagnostic and therapeutic methods for cancer
TWI827550B (zh) 2017-09-08 2024-01-01 美商建南德克公司 癌症之診斷及治療方法
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
CN114746410A (zh) * 2019-12-05 2022-07-12 阿斯利康有限公司 用于生产式(i)的方法和中间体
CN115710158A (zh) * 2021-08-23 2023-02-24 凯特立斯(深圳)科技有限公司 一种不对称催化制备替格瑞洛中间体的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
US6869966B2 (en) * 2002-09-30 2005-03-22 Banyu Pharmaceutical Co., Ltd. N-substituted-2-oxodihydropyridine derivatives
AU2007229552C1 (en) * 2006-03-29 2013-06-13 F. Hoffmann-La Roche Ag Pyridine and pyrimidine derivatives as mGluR2 antagonists
WO2009061761A2 (en) * 2007-11-06 2009-05-14 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic amines
ES2857649T3 (es) * 2012-03-01 2021-09-29 Array Biopharma Inc Inhibidores de serina/treonina cinasa
WO2015130976A1 (en) * 2014-02-27 2015-09-03 Canon U.S.A., Inc. Placement apparatus
ES2733495T3 (es) 2014-04-09 2019-11-29 Genentech Inc Proceso para la fabricación de medicamentos

Also Published As

Publication number Publication date
IL268690A (en) 2019-10-31
TW201945358A (zh) 2019-12-01
HRP20191306T1 (hr) 2019-10-18
TW201620897A (zh) 2016-06-16
TWI678366B (zh) 2019-12-01
KR20200038553A (ko) 2020-04-13
CN111777594A (zh) 2020-10-16
EP3129025B1 (en) 2019-05-15
IL248205A0 (en) 2016-11-30
CN112645927A (zh) 2021-04-13
NZ725450A (en) 2022-08-26
US10611753B2 (en) 2020-04-07
AU2020220208A1 (en) 2020-09-10
AR099989A1 (es) 2016-08-31
SI3129025T1 (sl) 2019-08-30
AU2015245743A1 (en) 2016-10-27
BR112016023391A2 (pt) 2017-08-15
KR20160133566A (ko) 2016-11-22
CA2945098A1 (en) 2015-10-15
SG11201608421XA (en) 2016-11-29
JP6723926B2 (ja) 2020-07-15
EP3494971A1 (en) 2019-06-12
RU2016139286A3 (pt) 2018-10-26
IL248205B (en) 2019-09-26
JP2020114817A (ja) 2020-07-30
JP6974524B2 (ja) 2021-12-01
JP2017510620A (ja) 2017-04-13
RU2684102C2 (ru) 2019-04-04
CN106659721A (zh) 2017-05-10
BR122020014933B8 (pt) 2022-12-13
KR102490955B1 (ko) 2023-01-19
MY196320A (en) 2023-03-24
AU2015245743B2 (en) 2020-09-24
MX2016013162A (es) 2017-04-27
US20200190061A1 (en) 2020-06-18
US20170022183A1 (en) 2017-01-26
TWI762806B (zh) 2022-05-01
ES2733495T3 (es) 2019-11-29
BR112016023391B1 (pt) 2022-08-09
PL3129025T3 (pl) 2019-11-29
ZA201607066B (en) 2018-05-30
CN106659721B (zh) 2021-01-01
BR122020014933B1 (pt) 2022-11-29
JP2021167321A (ja) 2021-10-21
RU2016139286A (ru) 2018-05-15
CA2945098C (en) 2022-10-04
EP3129025A4 (en) 2018-01-17
WO2015154674A1 (en) 2015-10-15
MX2020010384A (es) 2022-05-19
AU2020220208B2 (en) 2022-03-17
US11098028B2 (en) 2021-08-24
US20190367484A1 (en) 2019-12-05
EP3129025A1 (en) 2017-02-15
KR20230006043A (ko) 2023-01-10
MY188526A (en) 2021-12-18
CA3167641A1 (en) 2015-10-15
US11066389B2 (en) 2021-07-20
US20180134685A1 (en) 2018-05-17
CN111777594B (zh) 2023-06-27

Similar Documents

Publication Publication Date Title
BR112016023391A8 (pt) processo para a preparação de um composto de fórmula viii, processo para a preparação de 4-(2-(metilssulfonil)pirimidin-4-il)piridin-2(1h)-ona (vii), compostos,composições farmacêuticas,benzenossulfonatos, ácidos p-toluenossulfônico,forma b de ácido p-toluenssulfônico, forma ii do ácido naftalendissulfônico
BR112019003415A2 (pt) compostos de pirrolizina substituídos e usos dos mesmos
BR112018069612A2 (pt) compostos de pirroltriazina como inibidores de tam
CO2017006214A2 (es) Derivados de quinazolina utilizados para tratar el vih
ZA201804870B (en) Acid addition salts of piperazine derivatives
DOP2016000281A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
BR112016025132A2 (pt) compostos polifluorados agindo como inibidores de tirosina quinase de bruton
MA42592A (fr) Utilisation de dérivés de 2-(pyrazolopyridin-3-yl) pyrimidine en tant qu'inhibiteurs de jak
DK3433253T3 (da) Pyrimidinforbindelse som JAK-kinase-inhibitorer
BR112017009701A2 (pt) composto e métodos para a preparação de um composto
MA42919A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA42918A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
PE20160862A1 (es) Polimorfo de los inhibidores de la syk
DK3497081T3 (da) Fremgangsmåde til fremstilling af 4-ammonium-2,2,6,6-tetraalkylpiperidinylsalte
EA201500875A1 (ru) СОЛИ ПРОИЗВОДНЫХ 2-АМИНО-1-ГИДРОКСИЭТИЛ-8-ГИДРОКСИХИНОЛИН-2-(1Н)-ОНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3
BR112017028322A2 (pt) compostos, processo para a produção de compostos i, para a produção de compostos ii dos compostos iii e para a produção de compostos iii, compostos intermediários v e utilização dos compostos i
DK3233843T3 (da) Isoxazol-hydraxamsyreforbindelser som LPXC-hæmmere
GT201700058A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
UY36287A (es) COMPUESTO DE OBJETIVO A IL-23A y TNF-ALFA Y USO DEL MISMO
BR112015020716A2 (pt) processo para a preparação de (2-(4-(2-(1-isopropil-3-metil-1h-1,2,4-triazol-5-il)-5,6-diidrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-il)-1h-pirazol-1-il)-2-metilpropanamida (i) e composto
DK3692039T3 (da) Enantiomerer af substituerede thiazoler som antivirale forbindelser
DK3445743T3 (da) Prodrug af aminosyrederivat
BR112016029510A2 (pt) métodos para a preparação de um composto, e, composto intermediário.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/04/2015, OBSERVADAS AS CONDICOES LEGAIS